Moderate

Stimulant withdrawal (cocaine/amphetamine) — behavioural

Stimulant withdrawal · Psychiatry / Behavioural
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Withdrawal from cocaine or amphetamines (the 'crash') produces dysphoria, intense fatigue, hypersomnia, increased appetite, agitation and — importantly — depression with a significant suicide risk, rather than the autonomic instability of alcohol/opioid withdrawal. Management is largely supportive with attention to mood and safety.

Red flags

  • Suicidal ideation or plan (high risk during the crash)
  • Psychotic symptoms persisting (consider stimulant-induced or primary psychosis)
  • Chest pain or arrhythmia from recent use
  • Severe depression or inability to self-care
  • Evidence of rhabdomyolysis/AKI from prior agitation

Assessment

Differential diagnosis

  • Stimulant withdrawal / crash (dysphoria, hypersomnia, craving)
  • Major depressive episode (may be unmasked or precipitated)
  • Ongoing intoxication or mixed-drug use
  • Organic cause of low mood/fatigue (hypothyroidism, anaemia, infection)
  • Alcohol or sedative withdrawal (different features)

Investigations

  • Risk assessment for suicide (key — depression and craving peak in withdrawal)
  • Capillary glucose and observations
  • Toxicology and alcohol level
  • Bloods: FBC, U&E, LFTs, CK (if recent agitation/rhabdomyolysis), TFTs
  • ECG if recent stimulant use (ischaemia/arrhythmia)

Management

  • Confirm withdrawal rather than intoxication or another cause
  • Provide a calm, supportive environment with rest and hydration
  • Assess and manage suicide risk carefully — this is the main danger in stimulant withdrawal
  • Treat agitation or insomnia symptomatically if needed
  • Screen for and manage complications of prior use (cardiac, rhabdomyolysis)
  • Treat coexisting depression/psychiatric comorbidity with psychiatric input
  • Refer to substance-misuse services and provide harm-reduction advice
  • Arrange mental-health follow-up given relapse and suicide risk

Drugs & doses

No specific pharmacotherapy for stimulant withdrawal — supportive care is mainstay
Lorazepam — 1-2 mg PO for severe agitation/insomnia, short-term; max 4 mg/24h caution
Diazepam — 5-10 mg PO as an alternative for agitation
Antidepressants not started in ED — refer for assessment if depression persists

Disposition

Discharge most patients with substance-misuse referral and mental-health follow-up once suicide risk is assessed as low; admit or arrange urgent psychiatric review (MHA if needed) for high suicide risk or persisting psychosis.

Complications & pitfalls

  • Suicide during the depressive crash
  • Relapse to use
  • Prolonged depression and anhedonia
  • Cardiac sequelae of prior stimulant use
  • Social and functional decline

Exam pearls

  • The danger in stimulant withdrawal is depression and suicide, not autonomic collapse — prioritise risk assessment
  • There is no proven specific pharmacotherapy; treatment is supportive with mood/suicide focus
  • Craving and low mood peak early and then improve over days to a week
  • Persisting psychosis after the crash suggests a stimulant-induced or primary psychotic disorder
  • Use the presentation to engage the patient with substance-misuse and mental-health services

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.